HomeTrialNCT06150183
🔬NCT06150183Phase 1ACTIVE NOT RECRUITING

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

Study Summary

The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer. This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment41 participants
Primary Completion
Lead SponsorBioNTech SE
Data Retrieved2026-04-11 02:55:25.057750+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.